Key result
Extracellular vesicles offer promising post-MI cardioprotection with greater stability and lower immunogenicity than cell therapy.
Answers are grounded in this paper and cite their sources.
Extracellular vesicles represent a promising, off-the-shelf cell-mimetic therapy for cardioprotection and injury minimization following acute myocardial infarction.
Despite improvements in clinical outcomes following acute myocardial infarction, mortality remains high, especially in patients with severely reduced left ventricular ejection fraction (LVEF <30%), emphasizing the need for effective cardioprotective strategies adjunctive to recanalization. Traditional cell therapy has shown equivocal success, shifting the focus to innovative cardioactive biologicals and cell mimetic therapies, particularly extracellular vesicles (EVs). EVs, as carriers of non-coding RNAs and other essential biomolecules, influence neighbouring and remote cell function in a paracrine manner. Compared to cell therapy, EVs possess several clinically advantageous traits, including stability, ease of storage (enabling off-the-shelf clinical readiness), and decreased immunogenicity. Allogeneic EVs from mesenchymal and/or cardiac stromal progenitor cells demonstrate safety and potential efficacy in preclinical settings. This review delves into the translational potential of EV-based therapeutic approaches, specifically highlighting findings from large-animal studies, and offers a synopsis of ongoing early-stage clinical trials in this domain.
No takes yet. Share an insight, caveat, or question.
Barile et al. (2024) conducted a review in Acute myocardial infarction. Extracellular vesicles vs. Traditional cell therapy was evaluated. Extracellular vesicles represent a promising cardioprotective strategy after myocardial infarction, offering stability and decreased immunogenicity compared to traditional cell therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: